ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Premium IconPremium Help Menu
S&P 500
5,982.72
-0.84%
US Tech 100
21,112.40
-1.21%
Dow Jones
42,215.80
-0.70%
Brent Oil
75.20
-1.10%
Bitcoin
105,459.50
0.82%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Harrow Inc (HROWL) Quote

Harrow Inc

Harrow Inc (HROWL)

NASDAQ
25.385
-0.015
(-0.06%)
Closed June 18 4:00PM
15 min delayed - Upgrade to Realtime
25.385
0.00
(0.00%)
After Hours: 4:02PM
15 min delayed - Upgrade to Realtime

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
25.385
Bid
24.70
Ask
25.40
Volume
1,590
25.37 Day's Range 25.385
24.65 52 Week Range 25.73
Market Cap
931.618M
Previous Close
25.40
Open
25.37
Last Trade
1
@
25.37
Last Trade Time
Financial Volume
$ 40,356
VWAP
25.381
Average Volume (3m)
6,141
Shares Outstanding
36,699,553
Dividend Yield
8.49%
PE Ratio
-53.29
Earnings Per Share (EPS)
-0.48
Revenue
199.61M
Net Profit
-17.48M

About Harrow Inc

Harrow Health Inc is an ophthalmology-focused pharmaceutical company. The company is specialized in the development, production, and sale of medications that offer competitive advantages and serve unmet needs in the marketplace. Its cornerstone of ophthalmology program consists of proprietary Drople... Harrow Health Inc is an ophthalmology-focused pharmaceutical company. The company is specialized in the development, production, and sale of medications that offer competitive advantages and serve unmet needs in the marketplace. Its cornerstone of ophthalmology program consists of proprietary Dropless Therapy injectable and LessDrops topical formulations that are designed to address patient compliance issues and provide other compelling medical and economic benefits. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.harrow.com
Headquarters
Dover, Delaware, USA
Founded
-
Harrow Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker HROWL. The last closing price for Harrow was $25.40. Over the last year, Harrow shares have traded in a share price range of $ 24.65 to $ 25.73.

Harrow currently has 36,699,553 shares outstanding. The market capitalization of Harrow is $932.17 million. Harrow has a price to earnings ratio (PE ratio) of -53.29.

Ask ADVFN Intelligence (AI)

HROWL Latest News

More News
No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.1050.41534810126625.2825.425.2544625.28892432CS
40.2350.93439363817125.1525.425.11508525.27383709CS
120.0750.29632556301925.3125.524.99614125.27155382CS
26-0.000599999999999-0.0023635446867525.385625.5724.99527325.27401079CS
520.4351.7434869739524.9525.7324.65507725.29301196CS
1561.5856.6596638655523.825.7322.05684724.41007992CS
2600.4851.9477911646624.927.0522.051006525.15974887CS

HROWL - Frequently Asked Questions (FAQ)

What is the current Harrow share price?
The current share price of Harrow is $ 25.385
How many Harrow shares are in issue?
Harrow has 36,699,553 shares in issue
What is the market cap of Harrow?
The market capitalisation of Harrow is USD 932.17M
What is the 1 year trading range for Harrow share price?
Harrow has traded in the range of $ 24.65 to $ 25.73 during the past year
What is the PE ratio of Harrow?
The price to earnings ratio of Harrow is -53.29
What is the cash to sales ratio of Harrow?
The cash to sales ratio of Harrow is 4.67
What is the reporting currency for Harrow?
Harrow reports financial results in USD
What is the latest annual turnover for Harrow?
The latest annual turnover of Harrow is USD 199.61M
What is the latest annual profit for Harrow?
The latest annual profit of Harrow is USD -17.48M
What is the registered address of Harrow?
The registered address for Harrow is 850 NEW BURTON ROAD, SUITE 201, KENT, DOVER, DELAWARE, 19904
What is the Harrow website address?
The website address for Harrow is www.harrow.com
Which industry sector does Harrow operate in?
Harrow operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CEROCERo Therapeutics Holdings Inc
$ 19.92
(190.04%)
57.35M
ACXPAcurx Pharmaceuticals Inc
$ 0.8149
(165.35%)
337.39M
EYENEyenovia Inc
$ 6.96
(134.34%)
29.94M
RBNERobin Energy Ltd
$ 10.60
(92.03%)
45.44M
RELIReliance Global Group Inc
$ 2.20
(86.44%)
19.29M
SDSTStardust Power Inc
$ 0.186
(-52.10%)
39.42M
SHOTWSafety Shot Inc
$ 0.0161
(-45.97%)
12.35k
RUNSunrun Inc
$ 5.78
(-40.04%)
120.05M
SEDGSolarEdge Technologies Inc
$ 15.94
(-33.53%)
33.14M
GOVXGeoVax Labs Inc
$ 0.8924
(-32.39%)
2.64M
PCSAProcessa Pharmaceuticals Inc
$ 0.2632
(16.93%)
575.5M
GNLNGreenlane Holdings Inc
$ 0.0104
(-16.13%)
392.94M
HCTIHealthcare Triangle Inc
$ 0.022
(-16.67%)
356.57M
ACXPAcurx Pharmaceuticals Inc
$ 0.8149
(165.35%)
337.39M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 11.9373
(-7.75%)
143.55M

Discussion

View Full Feed
wshaw14 wshaw14 2 minutes ago
There would have been a public filing on any such purchase. They may or may not have any holdings now.
BTG
BuccaneerGoblin51 BuccaneerGoblin51 4 minutes ago
P.s. I don't know numbered posts, so don't know to which post you refer, but would read it if you copy and repost in reply?
AFFU
RomComDemon RomComDemon 5 minutes ago
Will do, I'm still pretty excited about this one, off to research I go🤙🏽
GTCH
shajandr shajandr 5 minutes ago
I expect now we will hear much more about FADEC and specifically FADEC 4 - and the design decision to automatically fail an engine when its FADEC fails. Nott knowing all the intricacies why that decision was made, on first impression it might have been a better idea to have the system notify the coc
BA
arizona1 arizona1 5 minutes ago
I for one would love to see Hospital Barbie.
Not likely Not likely 8 minutes ago
Likely a merger with a somewhat ‘clean’ ticker like this.

Needing to be audited for legality tells me they must have a legit entity to bring in.

It’s obs taken some time but it has to be for a reason if they choose to keep it current.

This ticker does
EEGI
gitreal gitreal 11 minutes ago
EXPECTING MEGA AABB NEWS IN NEXT 48 HOURS!!! MARK MY WORDS!!!

A stupid PR with new "mines" being acquired, followed by hundreds of millions of newly converted shares from Clive's Never-Ending, Toxic Note from Hell. Sounds like fun times coming!
AABB
Acme Investments Acme Investments 12 minutes ago
I just read your bio said day trader!! Lol 😂 Never trust a person who NEVER discusses their LOSSES!!
CGLCF
blue Hawaii blue Hawaii 13 minutes ago
dilution holding us back for now 
patience 
good luck
IONQ
$2.00 or no deal $2.00 or no deal 16 minutes ago
If this post receives at least 10 likes I will PAY for the documents.

As a reminder, I paid for the documents 4-5 times already!

Again, THIS post needs AT LEAST 10 likes and I will pay for and post BOTH documents IN FULL.

Thanks.
ELTP
pharao007 pharao007 17 minutes ago
Next fairytale
HyGro HyGro 18 minutes ago
Ain't going to happen. NICE doesn't like expensive personalized therapies, most new oncology therapies aren't getting funded. For example CAR-T, a well proven personalized therapy, took 5 years after approval for NICE to finally use their charity to fund a limit of 100 patients a year at a deep d
NWBO
weldman weldman 18 minutes ago
ween we sold TPTW @.10
TPTW
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 18 minutes ago
Is the business case for shorting AVXL evaporating?

Agree that it seems insane to pay 18.5% to short a stock that has the potential to hit 3 digits in 6 months.

The short interest is so high, so it cant just be MM's shorting as part of their daily manipulation.
AVXL
demonsmith demonsmith 19 minutes ago
I think there getting ready to uplist to otcqb to start there journey to Nasdaq uplist
PTAM
wshaw14 wshaw14 19 minutes ago
We should be hearing some kind of news soon.
BTG
$2.00 or no deal $2.00 or no deal 20 minutes ago
DAM you're good!

Now I know why they call you The King.

***** Literally TODAY *****

Elite MUST respond to Purdue's amended complaint by the end of.......................TODAY.
ELTP
wshaw14 wshaw14 20 minutes ago
We should be getting some kind of news soon.
SKE
wshaw14 wshaw14 21 minutes ago
Thanks for the info JD400.
MUX
weldman weldman 22 minutes ago
YES like we sold EWLL @.0052
EWLL
ron_66271 ron_66271 23 minutes ago
My Release Document is the Court Document.

41.6 comes from the GSA.

The Dual Track. JPM lost.
GSA settlement.


Meat. You have no substance.

Like;
Impossible Meat
Just a vegetable.

Just a mysteriou
JPM
blackcat blackcat 23 minutes ago
Indeed. Occurs to me that you could always sub in Desantis' wife, I think her name is Casey? She loves cosplay and she could hardly be worse than Noem.
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 23 minutes ago
Latest borrow fee for Anavex Life Sciences (AVXL) shares on Interactive Brokers: 18.5256% (annualized)

wow, that is nuts. just cover already.

Fidelity only at 8.125%, up, but nowhere near 18.5%

Pressure still building in the AVXL volcano.

AVXL
Konaploinks Konaploinks 24 minutes ago
Yep and 1 billion authorized. So we have a lot left to deal out for more acquisitions. If I were Niccolo I’d keep snapping up these quantum start ups that have worthwhile patents and brain trust in their employees. Good quantum scientists will dry up soon. It will be a scramble to find good qualifie
IONQ

Your Recent History

NASDAQ
HROWL
Harrow
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub
United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN Ltd - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads